Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2009 - 2017)
Biomarin Pharmaceutical (BMRN) recorded quarterly Current Deferred Revenue of $17.4 million in Q3 2017, up 1669.54% on a QoQ basis from $985000.0 in Q4 2016.
Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2009 - 2017) Analysis & Trends
Biomarin Pharmaceutical has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $17.4 million for Q3 2017.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $17.4 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $17.4 million (changed N/A YoY) and the FY2016 annual result came in at $985000.0, changed N/A from the prior year.
- Current Deferred Revenue climbed to $17.4 million in Q3 2017, from $985000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $17.4 million in Q3 2017 and troughed at $985000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Biomarin Pharmaceutical | 10.52 Bn | 8.29 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 17.43 Mn |
| Dec 31, 2016 | 985,000.00 |
| Sep 30, 2012 | 1.08 Mn |
| Jun 30, 2012 | 1.11 Mn |
| Dec 31, 2011 | 342,000.00 |
| Dec 31, 2009 | 86,000.00 |